The data reinforces acoramidis' competitive edge over tafamidis, likely supporting continued adoption. Monitor for potential guidance updates and upcoming label expansions. Stock could rally on the differentiated efficacy signals.
Price Chart
Executive Summary
BridgeBio presented new acoramidis data at Heart Failure 2026, showing a 34% reduction in cardiovascular hospitalizations versus tafamidis (indirect comparison), early separation in outpatient worsening heart failure within 30 days (HR 0.59, p<0.0001), and sTTR variability reduction associated with lower all-cause mortality (HR 0.56, p=0.014). These results strengthen acoramidis' differentiation as a near-complete TTR stabilizer and could support further market share gains in ATTR-CM.
Key Facts
- Acoramidis reduced cardiovascular hospitalizations by 34% vs tafamidis (RRR 0.66, 95% CI 0.46–0.95) in a matching-adjusted indirect comparison.
- Acoramidis reduced the risk of outpatient worsening heart failure by 41% vs placebo (HR 0.59, p<0.0001), with separation seen within 30 days and sustained through Month 30.
- Lower sTTR variability and higher achieved sTTR levels were independently associated with reduced all-cause mortality (HR 0.56, p=0.014 and HR 0.46, p=0.014).
- Acoramidis blunted NT-proBNP increase by ~50% across all subgroups vs placebo.
- Acoramidis is approved as Attruby in the US and under other brand names in multiple ex-US markets.
Financial Impact
Positive for acoramidis commercial prospects; no direct financial figures provided.
Risk Factors
- Indirect comparison limitations and potential unmeasured confounders vs tafamidis.
- Future clinical or regulatory setbacks could reverse positive sentiment.
- Competition from other ATTR-CM therapies (e.g., Pfizer's tafamidis, gene silencers).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291995 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $67.47 (−11.90%) |
Aug 26, 2026 5w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $67.47 (−14.99%) |
Aug 22, 2026 5w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $67.47 (−16.77%) |
Aug 17, 2026 6w ago | 8-K | $79.89 $72.38 | ▼ −9.40% | ▼ −7.87% | $67.47 (−15.54%) |
Aug 13, 2026 7w ago | Press Release | $79.86 $72.38 | ▲ +9.37% | ▲ +7.38% | $67.47 (+15.51%) |
Aug 10, 2026 7w ago | 8-K | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Aug 10, 2026 7w ago | Press Release | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Jul 13, 2026 11w ago | Insider Cluster | $83.08 $84.67 | ▲ +1.91% | ▼ −1.27% | $67.47 (−18.78%) |
Jun 28, 2026 13w ago | Press Release | $72.01 $84.02 | ▲ +16.68% | ▲ +16.96% | $67.47 (−6.30%) |
Jun 24, 2026 14w ago | 144 | $69.69 $82.93 | ▲ +19.00% | ▲ +18.47% | $67.47 (−3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access